Public Summary

Summary for ARTG Entry:	371894 METAGENICS GLUCOSAMINE INTENSIVE CARE
ARTG entry for	Medicine Listed
Sponsor	Metagenics (Aust) Pty Ltd
Postal Address	PO Box 675, VIRGINIA BC, QLD, 4014 Australia
ARTG Start Date	30/07/2021
Product Category	Medicine
Status	Active
Approval Area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . METAGENICS GLUCOSAMINE INTENSIVE CARE

Product Type Single Medicine Product **Effective Date** 30/07/2021

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Maintain/support connective tissue health

Aid/assist/helps connective tissue production/formation

Maintain/support bone health

Maintain/support bone strength

Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
- Linked indication - Decrease/reduce/relieve mild joint aches and pains
- Linked indication - Helps enhance/promote healthy joint function
- Linked indication - Decrease/reduce/relieve mild joint pain/soreness

Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
- Linked indication - Decrease/reduce/relieve mild joint stiffness
- Linked indication - Maintain/support joint mobility/flexibility

Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis

Helps maintain/support joint cartilage health

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.

Product presentation must only refer to mild joint symptoms.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).

Not to be taken by children under 2 years old (or words to that effect).

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

borax	**13 mg**
Equivalent: boron	1.5 mg
colloidal anhydrous silica	**20 mg**
glucosamine sulfate sodium chloride	**942 mg**
Equivalent: glucosamine sulfate	750 mg
manganese amino acid chelate	**47 mg**
Equivalent: manganese	7.5 mg
zinc amino acid chelate	**50 mg**
Equivalent: zinc	10 mg

Other Ingredients (Excipients)

citric acid
glycerol
hypromellose
magnesium stearate
maltodextrin
microcrystalline cellulose
povidone